A5103278306- Cholinesterase and Neurodegenerative Diseases
- Heart Failure Treatment and Management
- Pharmacogenetics and Drug Metabolism
- Pharmaceutical Economics and Policy
- Blood Pressure and Hypertension Studies
Ministry of Health of the Russian Federation
2019-2022
Federal Medical Research Centre for Psychiatry and Narcology
2019
The angiotensin-converting enzyme inhibitor enalapril is hydrolysed to an active metabolite, enalaprilat, in the liver via carboxylesterase 1 (CES1). Previous studies show that variant rs71647871 CES1 gene affects pharmacokinetics of on samples as well healthy volunteers. This study included 286 Caucasian patients with arterial hypertension who received enalapril. concentrations and enalaprilat were determined before subsequent intake drug 4 h after it high-performance liquid chromatography...
Variants in the CES1 gene encoding carboxylesterase 1 may affect metabolism of enalapril to active metabolite enalaprilat. It was shown that A allele rs71647871 and C rs2244613 led a decrease plasma enalaprilat concentrations. This study aimed estimate effect structural haplotypes containing pseudogene CES1P1, or hybrid CES1A2, on pharmacokinetics enalapril. We included 286 Caucasian patients with arterial hypertension treated Genotyping performed using real-time PCR long-range PCR. Peak...